Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Terminated Phase 1 Interventional

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05295927
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone, Apalutamide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Towson, Maryland • Omaha, Nebraska • Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Decision Aids to Improve Knowledge in Patients With Prostate Cancer

NCT03182998
View directory record Official record
Conditions
Prostate Cancer
Interventions
Internet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration, Laboratory Biomarker Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 25, 2026, 5:10 PM EDT
Terminated Not applicable Interventional

Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients

NCT00585117
View directory record Official record
Conditions
CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Esophageal Cancer
Interventions
PET imaging with CuATSM, PET imaging, PET CuATSM
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer

NCT00400517
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, thalidomide, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 120 Years · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 25, 2026, 5:10 PM EDT
Completed No phase listed Observational

Prostate Cancer Utilities and Cost-Effectiveness Analysis

NCT00203918
View directory record Official record
Conditions
Prostate Cancer
Interventions
Survey, interview, patient utility scores (i.e. patient preference weights)
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 25, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes

NCT03432897
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Olaparib Pill, Prostatectomy
Drug · Procedure
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 25, 2026, 5:10 PM EDT
Not yet recruiting Phase 2 Interventional

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

NCT07635524
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cu-NU101
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Newport Beach, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Not applicable Interventional

InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

NCT06703996
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Discussion, Medical Device Usage and Evaluation, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

NCT00038662
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
24
States / cities
Homewood, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Results available

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

NCT00939120
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Tolterodine ER 4mg, Placebo, Pre-randomization Dutasteride
Drug
Lead sponsor
Siami, Paul F., M.D.
Other
Eligibility
50 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newburgh, Indiana
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 25, 2026, 5:10 PM EDT
Recruiting No phase listed Observational

Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation

NCT07203482
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 95 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2050
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

NCT01560923
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Indoximod, Sipuleucel-T, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 25, 2026, 5:10 PM EDT
Active, not recruiting Not applicable Interventional

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NCT04396808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score)
Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
8
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 25, 2026, 5:10 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

NCT00243646
View directory record Official record
Conditions
Prostate Cancer
Interventions
External beam radiation, Lupron, Casodex
Radiation · Drug
Lead sponsor
Schiffler Cancer Center
Other
Eligibility
Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
3
States / cities
Seattle, Washington • Wheeling, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002703
View directory record Official record
Conditions
Prostate Cancer
Interventions
high-LET heavy ion therapy, low-LET photon therapy
Radiation
Lead sponsor
Proton Radiation Oncology Group
Other
Eligibility
Male only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Loma Linda, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 5:10 PM EDT
Recruiting Phase 1 Interventional

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
Interventions
225Ac-ETN029, 111In-ETN029
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 3 Interventional Results available

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapy, docetaxel
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
343
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel in Treating Patients With Relapsed Prostate Cancer

NCT00482274
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

NCT00928174
View directory record Official record
Conditions
Prostate Cancer
Interventions
IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 25, 2026, 5:10 PM EDT
Withdrawn Phase 1 Interventional

Phase I Trial of PACE for Metastatic Prostate Cancer

NCT03110588
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
PACE with Cabazitaxel (15 mg/m2), PACE with Cabazitaxel (20 mg/m2)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 25, 2026, 5:10 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059
View directory record Official record
Conditions
Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Interventions
ALTA2618
Drug
Lead sponsor
Alterome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
La Jolla, California • Denver, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients

NCT02614859
View directory record Official record
Conditions
Cancer of Prostate
Interventions
Observation and Bicalutamide, Metformin and Bicalutamide
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 25, 2026, 5:10 PM EDT